◆ 会议时间：2024年11月11日至14日
◆ 会议地点：英国 爱丁堡

◆ 会议简介：

2024年第36届际乳头瘤病毒大会暨基础、临床和公共卫生科学研讨会(IPVC)将于2024年11月11日至14日在英国爱丁堡举办，会议由国际乳头瘤病毒学会（IPVS）主办，大会将通过研讨会、邀请讲座、口头报告和海报会议等形式展示最新的研究结果，会议将包括基础科学、临床研究以及公共卫生、流行病学和实施科学三个主要主题。IPVC将汇集来自世界各地的研究人员、临床医生和其他相关卫生专业人士，一起分享在全球控制HPV疾病过程中的有关乳头瘤病毒及其相关疾病的知识和观点。未经许可禁止复制摘录转载本站任何内容-国际医学会议网（lingyuint.com）.

国际乳头瘤病毒学会（IPVS）是乳头瘤病毒研究领域的国际权威组织。IPVS成立于2000年，是一个由研究动物和人类乳头瘤病毒及其相关疾病的生物医学科学家组成的非营利性国际组织，IPVS的使命是为消除乳头瘤病毒相关疾病做出贡献。

IPVC 2024 – The 36th International Papillomavirus Conference & Basic, Clinical and Public Health Scientific Workshops

Date: NOVEMBER 11-14, 2024
Venue: EDINBURGH, UK

Organized by: International Papillomavirus Society (IPVS)

摘要征文投稿：

Monday, May 6, 2024 (23:59 GMT) - Abstract Submission Deadline

Mid July, 2024 - Abstract Notifications

Monday, July 1, 2024 - Late-breaking Abstract Submission Opening

Sunday, September 1, 2024 - Late-breaking Abstract Submission Deadline

点此提交摘要>>>Submit Abstract>>>

GUIDELINES FOR ABSTRACT SUBMISSION

All abstracts must be submitted via this webpage. Please note that the Conference Secretariat is not able to accept abstracts submitted via e-mail, fax or post.

• All abstracts must be submitted in English.
• Each abstract should not exceed 300 words.
• The abstract title should not exceed 25 words.
• The following structure must be followed when submitting an abstract:
  • Introduction
  • Methods
  • Results
  • Conclusions

Presentation Type

Please choose one of the following presentation types:

• Poster
• Poster Discussion (Short Oral)
• Oral Presentation

The Scientific Committee will determine whether the abstract will be accepted for presentation, with consideration given to the author’s preference.

Authorship

The submitting author should also be the author for correspondence. An individual may be the submitting author on any number of abstracts.

The presenting author may or may not be the submitting/corresponding author. An individual may be the presenting author on a maximum of 3 abstracts.

Commercial Independence Guidelines

The IPVS makes every effort to ensure the scientific program is free of commercial bias. As such, before submitting an abstract, please read the guidelines here.

 Notification for Peer Review Outcome

Notification of abstract acceptance or non-acceptance will be emailed to the person listed on the abstract as Presenting author.

Industry employees’ participation as presenters in the scientific program is only allowed if they agree to speak only on completely non-commercial topics, unrelated to any of their company’s products, such as:

• basic science research (e.g. pre-clinical research, or therapy discovery)
• process or methodologies of research unrelated to a specific disease or device
• mechanisms of action unrelated to a specific product

Basic Information

• Full first and family name(s) of submitting/corresponding author and all co-authors.
• Affiliation details: department, institution/hospital, city, state (if relevant), country.
• Abstract title – The title is limited to 25 words in UPPER CASE (e.g. COMMON BLEEDING DISORDERS)
• Abstract text – The text is limited to 300 words.
• Abstract topic – Abstracts must be allocated to a specific topic for the Scientific Program. Please choose from the list of topics. 
• Keywords – Please enter 1 to 3 keywords that define your abstract. The keywords must be in English and can include numbers.
• Conflict of interest disclosure – Abstract submitter will be required to disclose any conflict of interest in the submission form.
• Publication embargo – All abstracts will be published on the 1st day of the Conference (November 12, 2024)

SUBMISSION REQUIREMENTS

• Each abstract can contain up to three images (media files) and/or three tables. The maximum file size of each image or table is 700 KB.
• Please do not submit multiple copies of the same abstract.
• Original research and updated research are strongly recommended.
• The submitting/corresponding author is required to ensure that all co-authors are aware of the content of the abstract before submitting it to the Secretariat.
• All notifications regarding abstract status, including notifications regarding abstract submission, abstract acceptance and scheduling, will be sent to the presenting author. The presenting author will be responsible for informing the other co-authors about the status of the abstract. Please refer to your abstract by abstract ID sent to you in the confirmation email, in all correspondence regarding the abstract.
• The Committee will endeavor to schedule and allocate abstracts according to authors’ preferences but reserves the right to decide on the final form of presentation.
• One of the abstract authors must attend the Conference and present the abstract to ensure that the abstract is included in the Scientific Program.
• Only abstracts of presenting authors who have registered for the Conference and have paid the registration fee by the deadline will be scheduled for presentation.
• The identity of the presenting author can be changed until the deadline.
• All abstracts must be submitted and presented in clear English with accurate grammar and spelling.
• Upon submission, the submitting/corresponding author confirms that the abstract has been proofread and that all information is correct.

The submitting/corresponding author accepts that the content of the abstract cannot be modified or corrected after final submission and that it will be published exactly as submitted.

ABSTRACT SUBMITTERS’ DECLARATION

During abstract submission you will be asked to confirm that you agree to the following:

1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after final submission and I am aware that it will be published as submitted.
2. Submission of the abstract constitutes the consent of all authors to publication (e.g. Conference website, programs, other promotions, etc.)
3. The Abstract Submitter warrants and represents that no part of the information and content that they provide (Hereafter: the “Content“) to IPVC 2023 Conference, International Papillomavirus Society, and Kenes Group (Hereafter: the “Organizers“), nor the publication of any such Content by the Organizers, on the internet or otherwise infringes any third party rights, including but not limited to privacy rights and/or intellectual property rights.
4. The Abstract Submitter grants the Organizers a copyright license to reproduce, publish, translate, distribute, and display the text of the Content on a royalty-free, perpetual, irrevocable nonexclusive basis.
5. I herewith confirm that the contact details saved in this system are those of the presenting author, who will be notified about the status of the abstract. The presenting author is responsible for informing the other authors about the status of the abstract. The submitting author may request to be copied on the abstract correspondence.
6. I understand that the presenting author must be a registered participant.
7. The Organizers reserve the right to remove from publication and/or presentation an abstract that does not comply with the above.
8. I understand that I must select a specific Topic and Sub-Topic for my abstract allocation. Although the Committee will work hard to honor this selection, this cannot be guaranteed. The Committee reserves the right to change the Topic or Sub-Topic under which the abstract was originally submitted.

Suzanne Garland

IPVC 2024 Co-chair

Kate Cuschieri

IPVC 2024 Co-Chair

Sheila Graham

IPVC 2024 Co-chair

注册费：

◆ 参会对象：医生、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。